Patient Registry Software Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Patient Registry Software Market Trends and Insights

Implementation of Government Initiatives and Funding for Large-Scale Patient Registries

Public funding is transforming registries from discretionary tools into compliance requisites. The FDA’s TEMPO pilot, launched in December 2025, enables device makers to fulfill surveillance duties through structured registry submissions, resulting in approximately 30% cost savings for sponsors. Australia’s National Cancer Data Framework earmarked grants in 2025 to test a shared oncology-registry platform and automate stage-at-diagnosis capture from radiology reports. Within the European Medicines Agency’s DARWIN EU network, 30 data partners covering 160 million lives now require registries that export OMOP-formatted datasets for multinational studies. India’s Ayushman Bharat Digital Mission has linked over 6.5 billion health records to unique identifiers, making registry enablement a prerequisite for public-sector contracts. Collectively, these programs accelerate procurement cycles and favor vendors that ship out-of-the-box FHIR and OMOP connectors.

Rising Adoption of Electronic Health Records and Interoperability Mandates

The ONC HTI-4 Final Rule, effective August 2025, expanded the USCDI to version 4 and prohibited information blocking for matching and consent APIs, providing registry vendors with real-time access to standardized data ^{[1]Office of the National Coordinator for Health Information Technology, “HTI-4 Final Rule,” healthit.gov}. TEFCA, operational since December 2024, provides a nationwide query-based exchange, enabling registries to pull longitudinal records without one-off data-use agreements. Michigan’s CHRONICLE pilot proved that HL7 ADT feeds can populate chronic-disease registries at scale, although inconsistent ICD-10 coding still hampers analytics. Faced with this momentum, EHR incumbents, such as Oracle Health, embedded registry modules to defend their installed bases and monetize incremental data flows. FHIR compatibility has therefore become a core requirement for tenders.

Increasing Utilization of Registry Data for Post-Marketing Surveillance and Real-World Evidence

Sponsors now utilize registries to generate external comparators, safety signals, and evidence for label expansion. FDA guidance clarifying the use of registries in regulatory submissions reduced uncertainty and accelerated uptake. Datavant’s July 2025 acquisition of Aetion merged a 60 million-record connectivity fabric with causal-inference analytics, demonstrating a shift toward turnkey RWE stacks. In Europe, EMA guidelines drive demand for audit-ready traceability and role-based access controls ^{[2]European Medicines Agency, “DARWIN EU Overview,” ema.europa.eu}. Partnerships, such as IQVIA-Salesforce, integrate registry data with commercial CRMs, linking clinical outcomes to physician engagement strategies.

Growth of Chronic-Disease Burden Requiring Longitudinal Outcomes Tracking

Aging populations increase the prevalence of cardiovascular, oncological, and metabolic disorders. The American College of Cardiology’s registry processes data from 2,400 hospitals, setting quality benchmarks for interventions. SEER now captures stage at diagnosis for 95% of reportable cancers, yet gaps in chemotherapy data sustain demand for integrated EHR-registry tools. Diabetes registries are increasingly incorporating continuous glucose data via FHIR, thereby easing participant burden. WHO’s DHIS2-based clinical-registry platform, launched in 2025, offers free modules that could displace commercial vendors in low-income regions. Value-based contracts underscore the importance of real-time dashboards and risk adjustment.

Privacy and Data-Security Concerns Amid Expanding Data-Sharing Ecosystems

Change Healthcare’s February 2024 ransomware breach, affecting 100 million records, heightened scrutiny of third-party processors under HIPAA and GDPR. Ascension Health’s 2024 cyberattack exposed the operational fragility of interconnected systems. Fragmented EU and U.S. rules add 3-6 months to the activation of multinational registries, as Ireland’s registry task force observed in 2025. TEFCA’s patient-access features introduce identity-proofing liabilities that smaller vendors struggle to absorb. Consequently, many sponsors demand federated architectures that keep data on hospital servers, adding 15-20% to the total cost of ownership and slowing uptake among budget-constrained societies.

Shortage of Trained Clinical Abstractors and Informatics Personnel

A 2024 HIMSS survey showed a 22% vacancy rate for documentation specialists, with hiring cycles exceeding 120 days. Certified Tumor Registrar shortages persist at 15%, compounded by retirements and competition from remote work. Q-Centrix’s expansion of outsourced services eases, but does not close, the gap because many registries still require rapid, in-house abstraction for decision support. AI tools reduce the manual load, yet accreditation rules still require human oversight to prevent the misclassification of complex cases. The lag in workforce development means constraints will continue through at least 2027.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type of Registry: Pregnancy Registries Accelerate as FDA Streamlines Surveillance

Pregnancy and maternal-child registries experienced the fastest 14.65% CAGR to 2031, following the TEMPO pilot, which enabled obstetric-device sponsors to rely on registry data for post-market safety, thereby reducing compliance timelines. The Coordinated Registry Network’s FHIR guide further cut per-registry setup costs by 25% and enabled multi-sponsor collaboration. Disease registries retained 42.45% of the 2025 patient registry software market share, anchored by mature oncology and cardiovascular systems. Yet the regulatory tilt toward rare exposures favors pregnancy registries for sustained outperformance.

Oncology registries remain the largest disease sub-segment, while cardiovascular cohorts rapidly expand as structural-heart intervention data sets mature ^{[3]American College of Cardiology, “National Cardiovascular Data Registry,” acc.org}. Diabetes registries address device-data integration, and rare-disease groups collaborate across 24 European nations through ERDRI. Product registries for implants gain traction with EU conditional approvals, and quality-improvement programs evolve into real-time decision-support engines.

By Software Solution: Cloud SaaS Dominance Reflects Interoperability and Cost Pressures

Cloud-deployed platforms controlled 54.32% of 2025 patient registry software market share and are projected to grow at a 14.78% CAGR through 2031. Providers favor subscription pricing and automatic FHIR upgrades, while AI integration accelerates abstraction workflows. HEALWELL AI’s pending Orion Health acquisition unites 150 million lives on a global interoperability stack, illustrating scale advantages.

On-premise systems persist in defense and government settings where air-gapped networks are mandated; the DoD’s MHS GENESIS spans 3,600 sites worldwide. Hybrid models emerge, with edge nodes for low-latency capture and cloud analytics. Ireland’s registry roadmap recommends an OMOP-based cloud hub to end vendor lock-in and lower total cost.

By End User: Research Institutes Surge on Grant-Funded Cohorts and Precision Medicine

Hospitals accounted for 41.45% of 2025 revenue, while research institutes and academic medical centers led growth at a 15.65% CAGR, driven by NIH grants for precision-medicine cohorts. Projects such as Columbia University’s SC2K and Boston Children’s CumulusQ illustrate the convergence of registry and research data warehouses.

Pharma and device sponsors are the second-fastest segment, catalyzed by regulatory acceptance of registry-based external controls. Government agencies maintain steady use for public health surveillance, while specialty societies consolidate on multi-tenant SaaS to reduce per-registry costs. The shift highlights the rising demand for genomics integration, biospecimen tracking, and consent management that support large-scale precision medicine pipelines.

Geography Analysis

North America remained the largest region, accounting for 44.32% of the 2025 revenue, supported by CMS quality programs and the ACC’s multi-hospital cardiovascular network. HTI-4 and TEFCA sharply reduce data-exchange friction, while Canadian provinces consolidate on integrated records such as Alberta’s Netcare platform. Growth slows, however, as U.S. health systems prioritize EHR optimization over new registry rollouts amid budget pressure.

Asia-Pacific is the fastest-growing geography, advancing at a 13.54% CAGR through 2031. India’s ABDM has linked 6.5 billion health records, creating vast addressable cohorts for FHIR-enabled registries. Australia’s National Cancer Data Framework funds shared platforms, and China’s provincial-registry mandates expand demand despite localization constraints. Japan’s expansion of My Number health cards underpins registry readiness that accommodates kanji and hiragana data.

Europe accounts for approximately 25% of the patient registry software market. EHDS rules require registries to export OMOP datasets for secondary research by 2029, driving upgrades to open, cloud-native architectures. Ireland’s 2025 roadmap proposes a cloud hub across five disease areas to share costs, signaling broader regional consolidation. GDPR raises compliance expenses, yet clarity on pseudonymisation and federated queries speeds adoption. Emerging markets in the Middle East, Africa, and South America remain nascent but show proof-of-concept pilots supported by cloud infrastructure.

Regulatory Landscape

In the United States, registry platforms supporting regulated evidence generation are operating under a tightening mix of health IT and life-sciences requirements. The ONC HTI-4 Final Rule (effective August 2025) expanded USCDI to v4 and reinforced anti-information-blocking expectations around standardized access, which is pushing registry workflows toward FHIR-based ingestion and consent-aware APIs. On the life-sciences side, FDA guidance continues to formalize how real-world data from registries can support safety and regulatory decision-making. Expectations such as 21 CFR Part 11 for electronic records and signatures keep validation and audit trails central for registries used in clinical investigations.

In Europe, GDPR obligations and the European Health Data Space (EHDS) direction increase the emphasis on interoperable exchange, secure logging, and secondary-use governance. This elevates requirements for OMOP-compatible exports and federated query patterns already used in networks such as EMA DARWIN EU. Cross-border registry activation timelines remain sensitive to privacy and security expectations, and recent high-profile cyber incidents in healthcare have increased scrutiny of third-party processors, which strengthens demand for role-based access controls, traceability, and privacy-preserving linkage in registry implementations.

Value Chain Analysis

The value chain begins with data origination and capture inside hospitals, health systems, and specialty societies, where EHRs, lab systems, and imaging systems generate structured and unstructured inputs. Registry software vendors then deliver core capabilities, including cohort definition, data models such as OMOP, workflow and abstraction, analytics, and submission formats, along with integration layers such as FHIR, HL7 v2, ADT feeds, and APIs. Downstream participants include connectivity and linkage networks that enable privacy-preserving matching and enrichment, and end customers that operationalize outputs through government agencies and quality programs, academic medical centers, and life-sciences sponsors using registries for real-world evidence, post-market surveillance, and external comparators.

The main bottlenecks show up at ingestion and curation, driven by semantic variability across EHRs, inconsistent coding, and manual abstraction that remains constrained by workforce shortages and oversight requirements. This is increasing reliance on automation and partnerships across the chain, including privacy-preserving linkage collaborations (for example, Thermo Fisher Scientific with Datavant to incorporate tokenization within clinical research infrastructure) and investments to broaden de-identified research connectivity (for example, TriNetX collaborating with Regeneron on a network cited at roughly 300 million de-identified patients). Vendors are also productizing AI-enabled abstraction to reduce manual workload while keeping human-in-the-loop validation, with differentiation shifting toward interoperability accelerators, consent management, and audit-ready governance.

Market Opportunities and Future Outlook

Interoperability mandates and standards roadmaps create room for registry platforms that ship automated, standards-aligned extraction and submission rather than site-by-site custom interfaces. In the US, CMS Promoting Interoperability pathways that include active engagement with Clinical Data Registries (CDRs) tie performance reporting demand to registry connectivity, and ONC initiatives such as the 2026 Standards Version Advancement Process (SVAP) (opening voluntary adoption of updated US Core standards beginning August 29, 2026) increase the cadence of standards updates that vendors need to operationalize. These conditions favor cloud-deployed SaaS offerings and vendors that can package FHIR-based ingestion, consent-aware APIs, and submission tooling as repeatable modules.

Cross-border and multi-stakeholder programs also expand the need for interoperable registries that support OMOP export and federated governance, consistent with the EHDS framework adopted as EU Regulation 2025/327. Concrete opportunity areas include automated registry extraction and data submission using HL7 implementation guides such as the FHIR Registry Protocols and CREDS, along with embedded consent automation to reduce friction in secondary use, supported by industry guidance such as The Sequoia Project work on automated patient consent. Another near-term commercialization lane is attaching registries to expanding HIE footprints (for example, the Florida HIE transition to CRISP Shared Services beginning July 1, 2026) so registries can ingest more complete longitudinal records without one-off agreements.